| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. | Lancet Neurol | 2020 | 3.93 |
| 2 | Progressive patterns of neurological disability in multiple sclerosis and neuromyelitis optica spectrum disorders. | Sci Rep | 2020 | 0.75 |